Zacks Investment Research downgraded Aclaris Therapeutics Inc (NASDAQ:ACRS) to Sell in a report released today.
- Updated: September 30, 2016
Zacks Investment Research has downgraded Aclaris Therapeutics Inc (NASDAQ:ACRS) to Sell in a report released on Friday September 30, 2016.
Yesterday Aclaris Therapeutics Inc (NASDAQ:ACRS) traded -0.51% lower at $25.16. The company’s 50-day moving average is $22.28 and its 200-day moving average is $20.05. The last stock close price is up 25.51% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 88,241 shares of the stock were exchanged, up from an average trading volume of 75,397
See Chart Below
Aclaris Therapeutics Inc has a 52 week low of $10.99 and a 52 week high of $33.88 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 3 firms have issued a report on the stock. The consensus target price is $26.33 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About Aclaris Therapeutics Inc (NASDAQ:ACRS)
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. The Company has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.